Image Place holder

Tawee Tanvetyanon, MD, MPH

Specialty: Medical Oncology
Program: Thoracic Oncology

Call 1-888-MOFFITT

or call 1-888-MOFFITT


Cancer Types Treated: Lung Cancer, Mesothelioma, Thymoma

Dr. Tanvetyanon is a medical oncologist with expertise in thoracic as well as head and neck malignancy. He is specialized in lung cancer and mesothelioma. Services offered include a wide array of clinical trials, immunotherapy programs, and hyperthermic intraperitoneal chemotherapy (HIPEC) for malignant mesothelioma. In addition, Dr. Tanvetyanon is experienced in managing abnormal findings from low-dose CT lung cancer screening. Dr. Tanvetyanon is a health outcomes researcher as well as an epidemiologist. To date, he has published over 30 peer-review articles in medical journals including Journal of Clinical Oncology, Annals of Oncology, Head & Neck and Journal of Thoracic Oncology. His research is geared toward improving the quality of cancer care as well as developing of statistical model to predict outcomes.    

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology


  • Loyola University Chicago, Stritch School of Medicine, Illinois - Medical Oncology & Hematology


  • Albert Einstein Medical Center at Thomas Jefferson Medical College, Pennsylvania -

Medical School:

  • Chulalongkorn University in Bangkok, Thailand - MD
Participating Trials

Expansion of Enduring Infrastructure to Support Lung Cancer Screening Research

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)

A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB00100718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies
Intervention: Avelumab; MSB00100718C (Avelumab); PD 0360324; PF-04518600; PF-05082566 (utomilumab); utomilumab

A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Intervention: MAGE-A10c796T

A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Intervention: cisplatin

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Intervention: Not Applicable

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Intervention: Alimta (Pemetrexed); MM-121; Not Applicable; Pemetrexed; Taxotere (docetaxel); docetaxel

A Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Intervention: G-CSF; MESNA; NY-ESO-1c259T; cyclophosphamide; cytoxan (cyclophosphamide)

Novartis Pharmaceuticals trial entitled: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Intervention: INC280 (Capmatinib)

A Phase 2 Study of Transarterial Chemoperfusion Treatment with Cisplatin, Methotrexate and Gemcitabine in Patients with Unresectable Pleural Mesothelioma
Intervention: Gemzar (gemcitabine); cisplatin; gemcitabine; methotrexate

A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Intervention: AZD1775; MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
Intervention: 750009 (Rilotumumab); 765338 (AZD4547); 772256 (Palbociclib); AMG102 (Rilotumumab); AMP-514 (Durvalumab); AZD4547; BMN-673 (Talazoparib); BMS-936558 (Nivolumab); CP-675,206 (tremelimumab); Dexamethasone; Durvalumab; Erlotinib; GDC-0032 (Taselisib); Ipilimumab; MEDI4736 (Durvalumab); Nivolumab; Palbociclib; Rilotumumab; Talazoparib; Tarceva (Erlotinib); Taxotere (docetaxel); Yervoy (Ipilimumab); docetaxel; tremelimumab

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Intervention: Crizotinib; Not Applicable; Placebo; Xalkori (Crizotinib)

Smartphone-Based Assessment of Patient-Reported Outcomes Related to Receipt of Immunotherapy

A Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Intervention: AZD9291 (Osimertinib); MLN0128; Osimertinib; TAK-228 (MLN0128)

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)
Intervention: Adriamycin (doxorubicin); PM01183 (lurbinectedin); Topotecan; Vincristine; cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin

Early Detection of Cancer Progression: Leveraging Team Science

Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer
Intervention: X-396 (Ensartinib)

A Phase Ii, Open-Label, Multicenter, Single-Arm Study To Investigate TheEfficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage Ib, Ii, Iiia Or Selected Iiib Resectable And Untreated Non-Small Cell Lung Cancer
Intervention: Atezolizumab (Tecentriq)

A Phase I/II Study of Pembrolizumab and Vorinostat in Patients with Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)

A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer
Intervention: BGB324; Erlotinib; Tarceva (Erlotinib)

Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Intervention: ADI-PEG 20; Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Placebo; carboplatin; cisplatin

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Intervention: BMS-936558 (Nivolumab); BMS-986205; Ipilimumab; Nivolumab; Yervoy (Ipilimumab)

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)

A Phase I/Ib Trial of Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Pirfenidone; Taxol (paclitaxel); carboplatin; paclitaxel

A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients with Advanced Non-Small Cell Lung Cancer
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2; Nivolumab; Proleukin (Interleukin-2); TIL; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

Phase 1b/2 Study Of VX15/2503 In Combination With Avelumab In Advanced Non-Small Cell Lung Cancer
Intervention: Avelumab; MSB00100718C (Avelumab); VX15/2503

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Intervention: JNJ-61186372

Phase I/II Study of Nivolumab and Ipilimumab combined with Nintedanib in Non Small Cell Lung Cancer
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nintedanib; Nivolumab; Yervoy (Ipilimumab)

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
Intervention: Not Applicable; TSR-033; TSR-042

Randomized Study of Erlotinib vs. Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Intervention: Erlotinib; Not Applicable; Placebo; Tarceva (Erlotinib)

A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Intervention: GSK1120212 (Trametinib); Trametinib

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Intervention: Epacadostat; INCB024360 (Epacadostat); INCB039110; INCB050465

XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Intervention: Crizotinib; X-396 (Ensartinib); Xalkori (Crizotinib)

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
Intervention: ASG-22CE

A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
Intervention: Poziotinib

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042

A Phase 1/2 Trial of CV301 in Combination with Anti-PD-1 Therapy versus Anti-PD-1 Therapy alone in Subjects with Non-Small Cell Lung Cancer
Intervention: FPV-CV301; MVA-BN-CV301; Pembrolizumab (Keytruda)

Phase I/Ib trial of single agent PBF-509 and in combination with PDR001 for patients with advanced NSCLC
Intervention: PBF-509; PDR001

A Phase I/IB Trial of MEK162 in Combination with Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Intervention: Erlotinib; MEK162; Tarceva (Erlotinib)

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
Intervention: Paraplatin (carboplatin); carboplatin; cisplatin; etoposide

A Phase 1, Open-Label Dose Escalation Study of PF-04518600 as a Single Agent and in Combination with PF-05082566 in Patients with Selected Locally Advanced or Metastatic Carcinomas
Intervention: PF-04518600; PF-05082566 (utomilumab)

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


  • Maller B, Peguero E, Tanvetyanon T. Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma. J Immunother. 2018 May. Pubmedid: 29742520.
  • Chatwal MS, Tanvetyanon T. Malignant mesothelioma clinical trial combines immunotherapy drugs. Immunotherapy. 2018 Apr;10(5):341-344. Pubmedid: 29473471.
  • Kass KS, Velez-Cubian FO, Zhang WW, Toosi K, Tanvetyanon T, Rodriguez KL, Thau MR, Garrett JR, Moodie CC, Fontaine JP, Toloza EM. Effect of advanced age on peri-operative outcomes after robotic-assisted pulmonary lobectomy: Retrospective analysis of 287 consecutive cases. Geriatr Oncol. 2017 Mar;8(2):102-107. Pubmedid: 28041970.
  • Tanvetyanon T, Gray JE, Antonia SJ. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. Expert Opin Biol Ther. 2017 Mar;17(3):305-312. Pubmedid: 28064556.
  • Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug;10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
  • Tanvetyanon T, Creelan BC, Antonia SJ. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. Expert Rev Anticancer Ther. 2016 Sep;16(9):903-910. Pubmedid: 27488231.
  • Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, Cinciripini P, Collins B, David S, Davis J, Hitsman B, Hyland A, Lang M, Leischow S, Park ER, Purcell WT, Selzle J, Silber A, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Tucker-Seeley R, Urbanic J, Hooper MW, Weksler B, Whitlock CW, Wood DE, Burns J, Scavone J. Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2016 Nov;14(11):1430-1468. Pubmedid: 27799513.
  • Mifsud MJ, Tanvetyanon T, Mccaffrey JC, Otto KJ, Padhya TA, Kish J, Trotti AM, Harrison LB, Caudell JJ. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck. 2016 Nov;38(11):1628-1633. Pubmedid: 27098984.
  • Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck. 2016 Jun;38(6):863-870. Pubmedid: 26340707.
  • Robinson LA, Tanvetyanon T, Springett G, Fontaine J, Toloza E, Hodul P, Pimiento JM, Malafa M. Pulmonary metastasectomy for suspected pancreaticobiliary cancer. J Thorac Cardiovasc Surg. 2016 Jul;152(1):75-82. Pubmedid: 27050555.
  • Tanvetyanon T, Boyle TA. Clinical implications of genetic heterogeneity in multifocal pulmonary adenocarcinomas. J Thorac Dis. 2016 Dec;8(12):E1734-E1738. Pubmedid: 28149626. Pmcid: PMC5227290.
  • Glover JR, Velez-Cubian FO, Zhang WW, Toosi K, Tanvetyanon T, Ng EP, Moodie CC, Garrett JR, Fontaine JP, Toloza EM. Effect of gender on perioperative outcomes after robotic-assisted pulmonary lobectomy. J Thorac Dis. 2016 Dec;8(12):3614-3624. Pubmedid: 28149556. Pmcid: PMC5227215.
  • Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015 Jun;37(6):840-845. Pubmedid: 24623654.
  • Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB. Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care. J Oncol Pract. 2015 Jul;11(4):332-337. Pubmedid: 25991639.
  • Jacobsen PB, Lee JH, Fulp W, Siegel EM, Shibata D, Laronga C, Gray J, Tanvetyanon T, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Malafa M. Florida Initiative for Quality Cancer Care: Changes in Psychosocial Quality of Care Indicators Over a 3-Year Interval. J Oncol Pract. 2015 Jan;11(1):e103-e109. Pubmedid: 25352389. Pmcid: PMC4582141.
  • Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2015 Apr;51(4):376-382. Pubmedid: 25593015. Pmcid: PMC4459134.
  • Dilling TJ, Extermann M, Kim J, Thompson LM, Yue B, Stevens CW, Antonia S, Gray J, Williams C, Haura E, Pinder-Schenck M, Tanvetyanon T, Kim S, Chiappori A. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Nov;90(4):828-833. Pubmedid: 25216856.
  • Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Ann Surg Oncol. 2014 May;21(5):1480-1486. Pubmedid: 24158467.
  • Rodriguez K, Velez-Cubian F, Zhang WW, Tanvetyanon T, Thau M, Moodie C, Garrett J, Fontaine JP, Robinson L, Toloza E. Effects of pulmonary function and of smoking history on perioperative outcomes after robotic-assisted pulmonary lobectomy: retrospective analysis of 201 consecutive patients. Chest. 2014 Mar;145(3 Suppl):48A. Pubmedid: 24638644.
  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res. 2014 Mar;20(6):1644-1655. Pubmedid: 24429877. Pmcid: PMC4051132.
  • Rao NG, Han G, Greene JN, Tanvetyanon T, Kish JA, De Conti RC, Chuong MD, Shridhar R, Biagioli MC, Caudell JJ, Trotti AM. Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. Pract Radiat Oncol. 2014 Mar;3(3):229-233. Pubmedid: 24674369.
  • Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB. Changes in the care of non-small-cell lung cancer after audit and feedback: the Florida initiative for quality cancer care. J Oncol Pract. 2014 Jul;10(4):e247-e254. Pubmedid: 24737876.
  • Tanvetyanon T, Creelan BC, Chiappori AA. Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer. Cancer Control. 2014 Jan;21(1):32-39. Pubmedid: 24357739.
  • Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013 Oct;36(8):442-450. Pubmedid: 23994887. Pmcid: PMC3846277.
  • Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA. Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med. 2013 Mar;38(3):175-182. Pubmedid: 23354032. Pmcid: PMC3578161.
  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul;31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
  • May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck. 2013 Dec;35(12):1796-1800. Pubmedid: 23468387.
  • Tanvetyanon T, Finley DJ, Fabian T, Riquet M, Voltolini L, Kocaturk C, Fulp WJ, Cerfolio RJ, Park BJ, Robinson LA. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Ann Oncol. 2013 Apr;24(4):889-894. Pubmedid: 23136230.
  • Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Ne. 2012 Nov;10(11):1391-1398. Pubmedid: 23138167. Pmcid: PMC5726232.
  • Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. Lung Cancer. 2012 Jan;75(1):9-14. Pubmedid: 21864934.
  • Phillips KM, Jim HS, Small BJ, Tanvetyanon T, Roberts WS, Jacobsen PB. Effects of Self-directed Stress Management Training and Home-based Exercise on Stress Management Skills in Cancer Patients Receiving Chemotherapy. Stress Health. 2012 Dec;28(5):368-375. Pubmedid: 22972771.
  • Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr;18(7):2056-2065. Pubmedid: 22241789. Pmcid: PMC5157199.
  • Tanvetyanon T, Corman M, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Bepler G, Siegel E, Shibata D, Malafa M, Jacobsen PB. Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida. J Oncol Pract. 2011 Nov;7(6):e25-e31. Pubmedid: 22379428. Pmcid: PMC3219472.
  • Faul LA, Jim HS, Minton S, Fishman M, Tanvetyanon T, Jacobsen PB. Relationship of exercise to quality of life in cancer patients beginning chemotherapy. J Pain Symptom Manag. 2011 May;41(5):859-869. Pubmedid: 21330097. Pmcid: PMC3779914.
  • Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2011 Mar;6(3):553-558. Pubmedid: 21289520. Pmcid: PMC3839293.
  • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
  • Tanvetyanon T, Robinson L, Sommers KE, Haura E, Kim J, Altiok S, Bepler G. Relationship between Tumor Size and Survival among Patients with Resection of Multiple Synchronous Lung Cancers. J Thorac Oncol. 2010 Jul;5(7):1018-1024. Pubmedid: 20453687.
  • Tanvetyanon T. Quality-of-care indicators for non-small cell lung cancer. Cancer Control. 2009 Oct;16(4):335-341. Pubmedid: 19910920.
  • Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-692. Pubmedid: 19620591.
  • Tanvetyanon T, Qin D, Padhya T, Kapoor R, McCaffrey J, Trotti A. Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol. 2009 Jan;30(1):38-43. Pubmedid: 19027511.
  • Tanvetyanon T, Murtagh R, Bepler G. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab. J Thorac Oncol. 2009 Feb;4(2):268-269. Pubmedid: 19179909.
  • Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A. Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer. J Clin Oncol. 2009 Apr;27(12):1983-1991. Pubmedid: 19289616.
  • Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol. 2008 Oct;26(28):4610-4616. Pubmedid: 18824709.
  • Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct;3(10):1112-1118. Pubmedid: 18827606. Pmcid: PMC2639211.
  • Tanvetyanon T, Robinson L, Schell M, Strong V, Kapoor R, Coit D, BeplerG. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrena metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008 Mar;26(7):1142-1147. Pubmedid: 18309950.
  • Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer. 2008 Jul;113(1):150-157. Pubmedid: 18429004.
  • Tanvetyanon T. Cetuximab in head and neck cancer. N Engl J Med. 2008 Dec;359(25):2725-2726. Pubmedid: 19102011.
  • Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul;25(19):2741-2746. Pubmedid: 17602079.
  • Tanvetyanon T, Soares H, Djulbegovic B, Jacobsen P, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol. 2007 Dec;2(12):1091-1097. Pubmedid: 18090580.
  • Tanvetyanon T. Understanding the uncommon thoracic tumors. Cancer Control. 2006 Oct;13(4):252-253. Pubmedid: 17075561.
  • Tanvetyanon T, Stiff P. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006 Jun;17(6):897-907. Pubmedid: 16547070.
  • Tanvetyanon T, Choudhury A. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma. Cancer. 2006 Apr;106(7):1554-1559. Pubmedid: 16518817.
  • Tanvetyanon T, Garrity ER, Albain KS. Acute lung injury associated with vinorelbine. J Clin Oncol. 2006 Apr;24(12):1952-1953. Pubmedid: 16622272.
  • Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliative Care. 2006;22(4):281-285. Pubmedid: 17263055.
  • Tanvetyanon T. Reply to the article "The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer" by K.P. Weinfurt et al. (Ann Oncol 2005; 16: 579-584). Ann Oncol. 2005 Oct;16(10):1712-1713. Pubmedid: 15972282.
  • Tanvetyanon T, Clark J, Campbell S, Lo S. Neoadjuvant therapy: an emerging concept in oncology. South Med J. 2005 Mar;98(3):338-344. Pubmedid: 15813161.
  • Tanvetyanon T. Treatment of localized lymphoma. N Engl J Med. 2005 Jun;352(23):2449-2451. Pubmedid: 15944432.
  • Tanvetyanon T. Medical costs associated with chiropractic care. Arch Intern Med. 2005 Jun;165(11):1313-1314. Pubmedid: 15956016.
  • Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005 Jan;103(2):237-241. Pubmedid: 15597384.
  • Tanvetyanon T. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2005 Jan;97(1):70. Pubmedid: 15632382.
  • Tanvetyanon T. Talking about death with dying children. N Engl J Med. 2005 Jan;352(1):91-92. Pubmedid: 15635780.
  • Tanvetyanon T, Stiff P. Recurrent steroid-responsive pancreatitis associated with myelodysplastic syndrome and transformations. Leuk Lymphoma. 2005 Jan;46(1):151-154. Pubmedid: 15621795.
  • Tanvetyanon T, Hines E J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 2005 Apr;103(8):1756-1757. Pubmedid: 15751014.
  • Tanvetyanon T. Molecular prediction of recurrence of breast cancer. N Engl J Med. 2005 Apr;352(15):1605-1607. Pubmedid: 15832454.
  • Nand S, Tanvetyanon T. Proton pump inhibitors and iron deficiency: is the connection real?. South Med J. 2004 Sep;97(9):799. Pubmedid: 15455957.
  • Tanvetyanon T, Toor A, Stiff P. Post-transplant air-leak syndrome. Br J Haematol. 2004 Sep;126(6):758-758. Pubmedid: 15352978.
  • Tanvetyanon T, Stiff P. Second allogeneic transplantation using a reduced-intensity preparative regimen for relapsed myelofibrosis. Am J Hematol. 2004 Oct;77(2):204-205. Pubmedid: 15389913.
  • Tanvetyanon T. Which patient with a do-not-intubate order is a candidate for noninvasive ventilation. Crit Care Med. 2004 Oct;32(10):2148-2150. Pubmedid: 15483429.
  • Tanvetyanon T. Arterial thrombosis in systemic lupus erythematosus. N Engl J Med. 2004 Oct;351(18):1910-1911. Pubmedid: 15515221.
  • Tanvetyanon T, Nand S. Pancytopenia in hereditary haemorrhagic telangiectasia. Brit J Haematol. 2004 Nov;127(4):371. Pubmedid: 15521911.
  • Tanvetyanon T. Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol. 2004 Nov;172(5 Pt 1):2082. Pubmedid: 15540794.
  • Tanvetyanon T. Treatment of von Willebrand's Disease. N Engl J Med. 2004 Nov;351(22):2345-2346. Pubmedid: 15570685.
  • Tanvetyanon T. Screening for primary human immunodeficiency virus infection. Arch Intern Med. 2004 Mar;164(6):680-680. Pubmedid: 15037504.
  • Tanvetyanon T, Choudhury A. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa. Ann Pharmacother. 2004 Mar;38(3):418-421. Pubmedid: 14970365.
  • Tanvetyanon T, Nand S. Herpes zoster during treatment with arsenic trioxide. Ann Hematol. 2004 Mar;83(3):198-200. Pubmedid: 15064871.
  • Tanvetyanon T. HER-2 and fluorescent in situ hybridization to evaluate breast cancer. Jama. 2004 Jul;292(3):328. Pubmedid: 15265845.
  • Tanvetyanon T. Adjuvant treatment of breast cancer with exemestane. N Engl J Med. 2004 Jul;351(1):100-102. Pubmedid: 15237463.
  • Tanvetyanon T. Telephone psychotherapy and care management for depression. Jama. 2004 Dec;292(22):2720. Pubmedid: 15585725.
  • Tanvetyanon T, Ratanatharathorn V, Leopairat J. Mucoepidermoid carcinoma of the lung presenting as a cavitary lesion. J Med Assoc Thai. 2004 Aug;87(8):988-991. Pubmedid: 15471307.
  • Tanvetyanon T, Choudhury A. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol. 2004 Apr;171(4):1627. Pubmedid: 15017238.
  • Tanvetyanon T. Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients?. Med Hypotheses. 2004;63(4):764-765. Pubmedid: 15325030.
  • Tanvetyanon T, Leighton J. Life-sustaining treatments in patients who died of chronic congestive heart failure compared with metastatic cancer. Crit Care Med. 2003 Jan;31(1):60-64. Pubmedid: 12544994.
  • Tanvetyanon T, Stadtmauer EA, Kerson LA. Concurrent administration of interferon alfa-2b and beta-1a. Ann Pharmacother. 2003 Jan;37(1):77-79. Pubmedid: 12503938.
  • Tanvetyanon T, Tapaneeyakorn J. Octreotide for bleeding as a result of hepatocellular carcinoma invasion of the gastrointestinal tract. J Gastroenterol Hepatol. 2003 Feb;18(2):231-232. Pubmedid: 12542614.
  • Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Ann Pharmacother. 2003 Dec;37(12):1818-1820. Pubmedid: 14632593.
  • Sirisinha T, Ratanatharathorn V, Jirajarus M, Sirilerttrakul S, Silpakit C, Sirachainan E, Tanvetyanon T. The European Organization for Research and Treatment of Cancer quality of life questionnaire: translation and reliability study of the Thai version. J Med Assoc Thai. 2002 Nov;85(11):1210-1219. Pubmedid: 12546319.
  • Tanvetyanon T, Walkenstein M, Marra A. Inaccurate glucose determination by fingerstick in a patient with peripheral arterial disease. Ann Intern Med. 2002 Nov;137(9):W1-W1. Pubmedid: 12416976.
  • Tanvetyanon T, Leighton J. Severe anemia and marrow plasmacytosis as presentation of Sjogren's syndrome. Am J Hematol. 2002 Mar;69(3):233-233. Pubmedid: 11891816.
  • Tanvetyanon T, Dissin J, Selcer U. Hyperthermia and chronic pancerebellar syndrome after cocaine abuse. Arch Intern Med. 2001 Feb;161(4):608-610. Pubmedid: 11252123.
  • Tanvetyanon T, Cohn J. Eligibility for outpatient treatment with low-molecular-weight heparin in venous thromboembolism. Arch Intern Med. 2000 Mar;160(6):869-870. Pubmedid: 10737288.
  • Tanvetyanon T, Elmishad AG, Carbone M. Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?. Anticancer Res. 25(1B):429-433. Pubmedid: 15816607.